Premium
Evaluation of N‐type Ca 2+ channel currents in cultured rat superior cervical ganglion neurons
Author(s) -
Stoehr Sally J.,
Campbell Gregory W.,
Rock David M.
Publication year - 1997
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/(sici)1098-2299(199706)41:2<85::aid-ddr5>3.0.co;2-n
Subject(s) - electrophysiology , channel blocker , superior cervical ganglion , calcium channel , voltage dependent calcium channel , pharmacology , chemistry , neuroscience , medicine , biophysics , biology , calcium
Electrophysiological studies of the effects of test compounds on ion channel currents have been useful in the identification of novel therapeutic agents. Here, we examined the use of cultured superior cervical ganglion (SCG) neurons as a model system for the electrophysiological evaluation of N‐type Ca 2+ channels in vitro. As previously reported, Ca 2+ channel currents in acutely dissociated preparations of SCG neurons were mainly N‐type, as defined by inhibition of Ca 2+ channel current with the specific N‐type Ca 2+ channel blocker, ω‐conopeptides GVIA or MVIIA. However, a cultured preparation that could be used over an extended period of time would be more useful for drug discovery since acutely dissociated preparations require daily dissections. We found that with extended time in culture the amplitudes of Ca 2+ channel currents increased with time. While there was a reduction in the percentage of N‐type Ca 2+ channel component, the majority (70%) of Ca 2+ channel currents in long‐term cultured SCG neurons remained N‐type. A portion of the MVIIA‐resistant Ca 2+ channel current component was blocked by the ω‐conopeptide MVIIC and ω‐agatoxin IIIA, but not by ω‐agatoxin IVA, a pharmacological profile similar to Q‐type Ca 2+ channel current. These studies suggest that cultured SCG neurons would be useful for the study of N‐type Ca 2+ currents even after prolonged time in culture, and may also be used to indicate the selectivity of test compounds for other Ca 2+ channel subtypes. Drug Dev. Res. 41:85–90, 1997. © 1997 Wiley‐Liss, Inc.